Combination therapy aiming for a functional cure for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new combination of medicines to help your immune system control the hepatitis B virus, with the goal of stopping the need for long-term treatment. It may be an option for people who have taken or are currently taking hepatitis B medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have chronic hepatitis B and are either new to treatment or have already taken hepatitis B medications.
- You do not have advanced liver disease, liver cancer, or other serious health conditions.
- You have not used certain medications or vaccines that could interfere with the study in the past month or so.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have not had major surgery or donated a large amount of blood recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.